IOL Chemicals and Pharma Ibuprofen manufacturing facilities in Barnala clears USFDA inspection

Published On 2019-10-30 08:41 GMT   |   Update On 2021-08-17 06:31 GMT

Mumbai: IOL Chemicals and Pharmaceuticals (IOLCP) recently received a communication from US Food and Drug Administration (USFDA) with respect to an inspection conducted by the USFDA of Ibuprofen manufacturing facilities located at Trident Complex, Mansa Road in Barnala of Punjab.


The inspection was carried out between August 5 to 9, 2019.


Read Also: USFDA rebukes Torrent Pharma management of inadequacy, violations at multiple sites


The USFDA has concluded that inspection is 'closed' under 21 CFR part 20.64(d)(3), IOL Chemicals said in a filing with BSE.


IOLCP Pharma was established in 1986 and is a significant player in the Organic chemicals space. It has a wide presence across various therapeutic categories like Pain Management, Anti-diabetic, Anti-hypertensive, Anti Convulsants, etc.


Read Also: Sanofi opens digital biologics manufacturing facility in the US

Tags:    
Article Source : UNI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News